A Drug-drug Interaction Study of Avapritinib and Midazolam
Completed · Phase 1 · NCT04908176
Conditions: Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
At a glance
- Research payments reported, 2025
- $26,986
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Blueprint Medicines Corporation
- Tested
- Avapritinib (drug), midazolam (drug)
- Dates
- Started 2022-08-24; completion 2024-05-10
- Results posted
- Not yet
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
From ClinicalTrials.gov, last updated 2024-12-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blueprint Medicines Corporation reported $26,986 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven Attia, DO Hematology & Oncology · Jacksonville, FL
- Iyad Alnahhas, M.D., M.S. Neurology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Thomas Jefferson University $22,499
- Mayo Clinic Jacksonville $4,487
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.